Short Interest in Curaleaf Holdings, Inc. (OTCMKTS:CURLF) Declines By 6.6%

Curaleaf logo with Medical background

Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Get Free Report) was the target of a large decrease in short interest in January. As of January 15th, there was short interest totalling 6,765,700 shares, a decrease of 6.6% from the December 31st total of 7,246,500 shares. Based on an average daily volume of 1,464,200 shares, the short-interest ratio is presently 4.6 days.

Curaleaf Price Performance

CURLF stock traded down $0.02 during mid-day trading on Thursday, reaching $1.63. The company's stock had a trading volume of 1,849,876 shares, compared to its average volume of 820,549. Curaleaf has a fifty-two week low of $0.88 and a fifty-two week high of $6.40. The stock has a market cap of $1.07 billion, a PE ratio of -5.62 and a beta of 0.61. The company has a current ratio of 1.11, a quick ratio of 0.51 and a debt-to-equity ratio of 0.85. The company's 50 day moving average is $1.54 and its two-hundred day moving average is $2.48.

Wall Street Analysts Forecast Growth

CURLF has been the subject of several recent research reports. Cormark downgraded shares of Curaleaf from a "moderate buy" rating to a "hold" rating in a research report on Thursday, November 7th. Roth Capital raised shares of Curaleaf to a "strong-buy" rating in a report on Sunday, November 10th.

Read Our Latest Stock Analysis on Curaleaf

Curaleaf Company Profile

(Get Free Report)

Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.

See Also

Should You Invest $1,000 in Curaleaf Right Now?

Before you consider Curaleaf, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.

While Curaleaf currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Nuclear Energy’s Comeback: 7 Stocks to Watch in 2025

Nuclear Energy’s Comeback: 7 Stocks to Watch in 2025

Nuclear energy is making a resurgence! Watch to find out which seven nuclear energy stocks could deliver long-term gains in the transition to cleaner energy.

Related Videos

3 Stocks That Wall Street Insiders Can’t Stop Buying

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines